Given the task definition and input, reply with output. In this task, you are given a text of many news articles seperated by special token "|||||". Your task is to summarize them.

An antibody from an HIV-infected person has successfully neutralized 98 percent of HIV isolates tested, including the lion’s share of strains resistant to other antibodies of the same class, US scientists have found. 
  
 The striking efficiency of the powerful antibody, named N6, makes it an ideal candidate for further research to treat or prevent HIV infection, scientists from the National Institutes of Health, the largest biomedical research agency in the world, have stated. 
  
 Read more 
  
 Scientists scrutinized the evolution of N6 over time to understand how exactly it managed to develop the ability to potently neutralize the majority of HIV strains. 
  
 Researchers say that identifying broadly neutralizing antibodies against HIV has been a real challenge because the virus rapidly changes its surface proteins to avoid recognition by the immune system. 
  
 In 2010, scientists at National Institute of Allergies and Infectious Diseases (NIAID’s) Vaccine Research Center (VRC) discovered an antibody called VRC01 that can stop up to 90 percent of HIV strains from infecting human cells. 
  
 “Like VRC01, N6 blocks infection by binding to a part of the HIV envelope called the CD4 binding site, preventing the virus from attaching itself to immune cells,” researchers said in a press release published on Tuesday. 
  
 Read more 
  
 Findings from the latest study showed that N6 developed a “unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains. This allows N6 to tolerate changes in the HIV envelope, including the attachment of sugars in the V5 region, a major mechanism by which HIV develops resistance to other VRC01-class antibodies.” 
  
 The new findings suggest that N6 could pose advantages over VRC01, researchers noted, adding that due to its potency, N6 may offer "stronger and more durable prevention and treatment benefits, and researchers may be able to administer it subcutaneously (into the fat under the skin) rather than intravenously." 
  
 According to UNAIDS, there were approximately 36.7 million people worldwide living with HIV/AIDS at the end of 2015. Of these, 1.8 million were children younger than 15 years old. The vast majority of people living with HIV are from low- and middle-income countries. 
  
 The WHO estimated that currently only some 54 percent of people with HIV know their status. ||||| The antibody could prove important in potentially treating or preventing HIV infection. 
  
 Scientists from the National Institutes of Health (NIH) have identified a powerful antibody that neutralizes 98% of HIV strains tested, including 16 of 20 strains resistant to other similar antibodies. 
  
 This antibody, named N6, could prove important in potentially treating or preventing HIV infection. 
  
 Because the HIV virus rapidly changes, evading recognition by the immune system, it's been difficult to identify neutralizing antibodies. In 2010, scientists at the National Institute of Allergy and Infectious Diseases' Vaccine Research Center discovered such an antibody, VRC01, that could stop up to 90 percent of HIV strains from infecting human cells. 
  
 According to a release from NIH, N6 acts like VRC01 by blocking "infection by binding to a part of the HIV envelope called the CD4 binding site, preventing the virus from attaching itself to immune cells." 
  
 Intravenous infusions of VRC01 to safely prevent HIV infection in humans are currently in clinical trials, but N6's potency may offer stronger and more durable prevention and treatment benefits, including administering it subcutaneously rather than intravenously. |||||

Scientists at the National Institutes of Health may have just discovered a powerful new tool in the fight against HIV. According to a press release, a newly identified antibody called N6 found in an HIV-infected person could successfully neutralize 98% of HIV isolates, including 16 of 20 HIV strains that are resistant to similar antibodies. Researchers published their findings Tuesday in Immunity. N6 could be more effective than another antibody, VRC01, that was discovered in 2010 and is currently in clinical trials. Out Magazine reports VRC01 could stop up to 90% of HIV strains. N6 works by binding to the HIV envelope and preventing it from attaching to the body's immune cells. It's hard to find antibodies that are as effective as N6 appears to be at attaching themselves to HIV because HIV quickly changes its surface proteins. N6 gets around that problem by focusing on parts of the HIV envelope that don't change very much. Scientists say N6 may be able to be developed to treat or prevent HIV infection. In 2015, more than 36 million people worldwide—nearly 2 million of them children—had HIV/AIDS, RT reports. It's estimated only 54% of people know whether or not they have HIV. ("Patient Zero," who brought AIDS to the US, actually didn't.)